A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Pfizer

Status: Active, not recruiting

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT06735742

C3441045

Details and patient eligibility

About

The purpose of this study is to learn about the safety of TALZENNA for the patients with breast cancer that cannot be removed by surgery and has come back. These participants also have a past treatment with medicines that try to stop the growth of cancer cells.

This study is seeking for participants who:

• have breast cancer that cannot be removed by surgery and has come back
• have not used this medicine before. All patients in this study will receive TALZENNA according to the prescriptions.

Patients will be followed up to 52 weeks (12 months) from the day of start of treatment start (Day 1). However, in cases where treatment has been completed or stopped less than 52 weeks (12 months) after the start of giving study medicine, the participants will be checked until completion (discontinuation) of treatment.

Enrollment: 3 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with BRCA mutation-positive and HER2- negative unresectable or recurrent breast cancer with a history of cancer chemotherapy
• No history of previous use of this drug

Exclusion criteria

• None